RAS LSS Consulting

Struggling to bring your innovation to market? The odds are steep - only 1 in 10,000 medicines make it from the lab to the market. The path is complex, with hurdles in #RandD, #RegulatoryApprovals, and #MarketDifferentiation.   At #RASLSSConsulting, we don't increase the odds of success...you do. We just operate behind the scenes, delivering #Insights that help you take bold #Decisions with confidence.   🔍 Watch our video to learn more, or reach out to see how we can help. #RASLSSConsulting - guiding you all the way, from lab to market. #RASLifeScienceSolutions #PharmaConsulting #LifeSciences #Innovation #Strategy #GetInTouch #Sevices #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #ManagementConsulting #MatchMaking #RandSupportServices #PortfolioOptimization #ConferenceCoverage #MarketEntryStrategy #PartnerIdentification

Sanofi Acquires #GreaterChinaRights for #Aficamten from CORXEL Pharmaceuticals, Expanding #HCMTreatment Reach Cytokinetics has announced that Sanofi will acquire exclusive rights from CORXEL Pharmaceuticals (CORXEL) to develop and commercialize #aficamten in #GreaterChina for the treatment of #obstructive and #nonobstructive #hypertrophiccardiomyopathy (HCM). #Aficamten is a next-generation #cardiacmyosininhibitor being developed as a potential treatment for HCM. In 2020, CORXEL Pharmaceuticals (formerly Ji Xing) secured the rights to develop and commercialize #aficamten in #GreaterChina, including the #Chinesemainland, #HongKongSAR, #MacauSAR, and #Taiwan, as part of Cytokinetics' global registration programs. The drug has been granted #BreakthroughTherapyDesignation by the #CenterforDrugEvaluation of #China’sNationalMedicalProductsAdministration for the treatment of symptomatic #obstructivehypertrophiccardiomyopathy (oHCM). Recently, a New Drug Application for aficamten tablets for the treatment of oHCM was accepted for Priority Review. Sanofi will acquire CORXEL Pharmaceuticals' rights to aficamten in Greater China for an undisclosed sum. Cytokinetics remains eligible for up to $150 million in development and commercial milestone payments from Sanofi, as well as royalties ranging from the low-to-high teens on future aficamten sales in Greater China. Additionally, Cytokinetics will receive further undisclosed payments following the agreement between Sanofi and CORXEL. Detailed news: https://lnkd.in/d7FqrAgW Follow our page for more industry updates: https://lnkd.in/de5zNWmK Know more about #RASLSSConsulting: https://lnkd.in/d_daJ5Xv #Sanofi #CorxelPharmaceuticals #Aficamten #HCMTreatment #Obstructivehypertrophiccardiomyopathy #RASLSSConsulting #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #MarketExpansion #PartnerIdentification

Saudi Arabia is making significant strides in its healthcare sector, as evidenced by the recent signing of a ground breaking #MemorandumofUnderstanding (MoU) with Vertex Pharmaceuticals at the inaugural CPHI Middle East. This strategic partnership aims to #localize #genetherapymanufacturing, marking a pivotal moment in the #Kingdom's journey towards becoming a #globalbiotechnologyhub by #2040. By establishing domestic production capabilities, Saudi Arabia aims to reduce reliance on imports, enhance accessibility to #lifesavingtreatments, and stimulate #economicgrowth. Vertex Pharmaceuticals will share its expertise and cutting-edge technology with #SaudiArabianresearchers and #scientists, fostering a #cultureofinnovation and #accelerating the development of #localtalent. The partnership will also invest in #traininganddevelopment programs to equip Saudi professionals with the skills and knowledge necessary to excel in the field of biotechnology, ensuring a sustainable pipeline of skilled talent. This strategic collaboration is expected to attract significant #investments of up to $266 million (SAR 1 billion) over the next five years, further bolstering #SaudiArabia's position as a regional leader in biotechnology and healthcare innovation. By prioritizing research, development, and local manufacturing, the Kingdom aims to improve patient outcomes, enhance healthcare accessibility, and drive economic diversification. Detailed News: https://lnkd.in/dk-Fb8Ju Follow our page for more industry updates: https://lnkd.in/de5zNWmK Know more about #RASLSSConsulting: https://lnkd.in/d_daJ5Xv #Vertex #CGT #CellAndGeneTherapy #SaudiArabia #RASLSSConsulting #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #MarketExpansion #PartnerIdentification

Skyhawk Therapeutics, a clinical-stage biotechnology company, announced that the #AustralianHumanResearchEthicsCommittees (HREC) has approved the use of #SKY0515 for up to 12 weeks in its ongoing #Phase1trial for #Huntington’sDisease (HD). The #HREC also approved the inclusion of #VolumetricMRI (vMRI) measurements as an exploratory endpoint in the study. These measurements target brain regions affected by HD, offering additional insights into the impact of SKY-0515 on patients. Skyhawk Therapeutics is thrilled to extend treatment duration for #Huntington’s patients after achieving a 72% reduction in #huntingtinmRNA (HTT) in the healthy volunteer portion of the study. The rigorous evaluation and approval of both the treatment extension and the #vMRI measurements by the HREC are greatly appreciated, as they are seen as enhancing the demonstration of SKY-0515's potential and potentially accelerating the path to pivotal trials. SKY-0515 is an investigational #oralsmallmoleculeRNAsplicing modifier developed using Skyhawk’s proprietary RNA-splicing platform. It is designed to reduce #HTT and #PMS1proteins, the latter being a key driver of #somaticCAGrepeat expansion and #HDpathology. Detailed news: https://lnkd.in/gjDTxeXc Follow our page for more industry updates: https://lnkd.in/de5zNWmK Know more about #RASLSSConsulting: https://lnkd.in/d_daJ5Xv #Skyhawktherapeutics #SKY0515 #Huntingtonsdisease #HREC #VolumetricMRI #Oralsmallmolecule #RASLSSConsulting #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #MarketExpansion #PartnerIdentification

Huawei and Ministry of Health Saudi Arabia have joined forces to revolutionize #healthcare in the Kingdom. This #strategicpartnership leverages Huawei #Cloud's cutting-edge technology to build a #robustdigitalhealthcareinfrastructure and #improvedpatientoutcomes.   The partnership focuses on creating a #unifiednational #healthcaredigitalplatform to streamline operations, facilitate data sharing, and enhance patient access to services. Additionally, it aims to utilize #AIpoweredsolutions to improve diagnostic accuracy, expedite treatment plans, and personalize healthcare services. To drive innovation, an #AIinnovationlaboratory will be established to foster research and development in AI-driven healthcare solutions. Investing in the training and development of healthcare professionals will ensure a skilled workforce capable of harnessing the power of digital technologies. Finally, implementing #nextgenerationhealthcaremanagementsystems will optimize #resourceallocation, improve #operationalefficiency, and #enhancepatientexperience.   By combining Huawei's expertise in #ICTinfrastructure and solutions with the Ministry of Health's deep understanding of the healthcare sector, this partnership aims to accelerate #SaudiArabia's #digitaltransformation journey and position the Kingdom as a #globalleader in #healthcareinnovation.   Detailed News: https://lnkd.in/dJdHY5_s Follow our page for more industry updates: https://lnkd.in/de5zNWmK Know more about #RASLSSConsulting: https://lnkd.in/d_daJ5Xv #Huawei #DigitalHealth #AI #SaudiArabia #RASLSSConsulting #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #MarketExpansion #PartnerIdentification

🌟 De Novo FDA Approvals in November 2024! 🌟 In November, the FDA approved five ground breaking #NewDrugs, marking important progress in the #Pharmaceutical industry. These #BreakthroughTherapies bring renewed hope and expanded treatment options for patients worldwide. It’s inspiring to see such advancements shaping the future of healthcare! Syndax Pharmaceuticals Jazz Pharmaceuticals BridgeBio AOP Health Bracco #USFDA #FDAApprovals #Pharmaceuticals #PharmaInnovation #BreakthroughTherapies #PatientCare #Revuforj #Ziihera #Attruby #Rapiblyk #Iomeron #RASLSSConsulting #MarketIntelligence #MarketResearch #MarketEntryStrategy #CompetitiveIntelligence #StrategySupport #PortfolioOptimization Know more about #RASLSSConsulting: https://lnkd.in/d_daJ5Xv Follow our page for more industry updates: https://lnkd.in/de5zNWmK

Gilead Sciences and Tubulis GmbH have entered into an exclusive option and license agreement to discover and develop an antibody-drug conjugate (ADC) targeting a solid tumor! Through this collaboration, Gilead Sciences will gain access to Tubulis GmbH’ proprietary #Tubutecan and #Alco5 platforms. The two companies will work together to determine the optimal technology to deploy, with Tubulis leading efforts in discovery and early development. The focus will be on designing a #topoisomeraseIinhibitorbasedADC candidate with enhanced biophysical properties and stability to address challenges such as durability and #offtargettoxicity. Gilead Sciences has a strong track record of developing therapies that offer significant advancements in treatment, making them an ideal partner to leverage our technology platforms. This aligns with Gilead’s vision to transform the #ADClandscape. While Tubulis GmbH remains dedicated to advancing our own #clinicaldevelopmentprograms, Gilead Sciences is selectively forming #partnershipswithindustryleaders. Tubulis will lead early-stage research and development activities for the ADC program, while Gilead will take over further development and commercialization if the option is exercised. Detailed news: https://lnkd.in/dyXNEZXd Follow our page for more industry updates: https://lnkd.in/de5zNWmK   Know more about #RASLSSConsulting: https://lnkd.in/d_daJ5Xv #GileadSciences #Tubulis #StrategicPartnerships #Solidtumor #ADCLandscapes #Antibodydrugconjugates #RASLSSConsulting #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #MarketExpansion #PartnerIdentification

PureHealth, one of the largest healthcare groups in the #MiddleEast, has reported a remarkable increase in the use of #Pura, its AI-powered app, since its initial launch in October 2023. With over 140,000 downloads, Pura is empowering individuals to take control of their #health and #wellbeing.  Pura has taken another step forward by launching a dedicated #diabetescare module. This new feature simplifies #diabetesmanagement by offering #realtimeglucosetracking and #personalizedmealplans. By integrating with continuous glucose monitoring devices and connecting to PureHealth's Diabetes Command Center, Pura empowers both patients and healthcare providers. Patients can take control of their health with actionable insights, while healthcare providers gain secure access to patient data for more effective monitoring and management. Beyond diabetes management, Pura offers a range of features to improve overall health. These include personalized health insights tailored to individual needs, seamless integration with wearable devices to track vital #healthmetrics, gamified challenges to encourage healthy habits, and convenient access to healthcare services through #telemedicine and #inpersonappointments. Pura is integrated with all hospitals and clinics in PureHealth’s network to make the patient journey more seamless. By leveraging AI and advanced technology, Pura provides users with tools to make informed decisions about their health. The app's user-friendly interface and personalized recommendations make it easy for individuals to stay on top of their health goals. PureHealth's commitment to digital innovation is evident in the development of Pura. The app is designed to enhance the #qualityoflife and #longevity, making healthcare more accessible and convenient for individuals across the region. Detailed news: https://lnkd.in/dywMTQ37 Follow our page for more industry updates: https://lnkd.in/de5zNWmK Know more about #RASLSSConsulting: https://lnkd.in/d_daJ5Xv #PureHealth #PuraApp #DigitalHealth #AI #Diabetes #RASLSSConsulting #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #MarketExpansion #PartnerIdentification

India Becomes Third Country to Launch Dr. Reddy's Laboratories' #Toripalimab, a Next-Gen Immuno-Oncology Therapy! Dr. Reddy's Laboratories Ltd., in partnership with Shanghai Junshi Biosciences Co Ltd has introduced #Toripalimab in India under the brand name #Zytorvi®. #Toripalimab, a next-generation PD-1 inhibitor, is the first #immuno-#oncology therapy approved by leading #global #regulatorybodies, including the #USFDAFDA, #EMA, #MHRA, and #DCGI, for treating adults with #recurrent or #metastatic #nasopharyngeal #carcinoma (RM-NPC). With this launch, India becomes the third country, following the #UnitedStates and #China, to gain access to this ground breaking therapy within the same year as its U.S. debut. #Toripalimab is approved as a first-line treatment for adults with metastatic or recurrent locally advanced #nasopharyngeal #carcinoma (NPC) when used in combination with standard #chemotherapy (#gemcitabine and #cisplatin), offering a 48% reduction in the risk of disease progression or death compared to #chemotherapy alone. Additionally, it is indicated as #monotherapy for patients with recurrent or #metastaticNPC who have experienced disease progression following #platinumbasedchemotherapy. The introduction of Toripalimab marks a crucial advancement for patients in India diagnosed with nasopharyngeal carcinoma (NPC). As a next-generation PD-1 inhibitor, it addresses a critical unmet need for this rare and complex disease, providing enhanced outcomes for patients in advanced stages. India ranks among the top five countries worldwide for NPC disease burden, with more than 6,500 new cases recorded in 2022, according to #GLOBOCAN. The highest incidence rates of this uncommon cancer are reported in the north-eastern states, particularly Nagaland. Detailed news: https://lnkd.in/dQpMUhWG Follow our page for more industry updates: https://lnkd.in/de5zNWmK Know more about #RASLSSConsulting: https://lnkd.in/d_daJ5Xv #DrReddysLaboratories #ShangaiJunshiBiosciences #Carcinoma #Nasopharyngealcarcinoma #MetastaticNPC #Chemotherapy #Monotherapy #NPCdiseaseburden #immunotherapy #RASLSSConsulting #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #MarketExpansion #PartnerIdentification #Oncology #Immunology

CStone Pharmaceuticals and Pharmalink have formed a #strategicpartnership to bring #sugemalimab, a groundbreaking immunotherapy treatment, to patients in the Middle East and North Africa (MENA) region and South Africa. #Sugemalimab is designed to target PD-L1, a protein that helps cancer cells evade the immune system. By blocking PD-L1, sugemalimab can help the immune system identify and attack cancer cells. By leveraging Pharmalink's strong market presence and commercial expertise, CStone Pharmaceuticals seeks to accelerate the availability of sugemalimab to patients in need. This partnership underscores CStone's commitment to globalizing its innovative therapies and improving patient outcomes worldwide. This collaboration aims to provide patients with advanced-stage cancers, such as lung cancer, with a much-needed treatment option. By expanding access to sugemalimab, CStone and Pharmalink hope to improve patient outcomes and quality of life. Detailed News: https://lnkd.in/gDX9jS35 Follow our page for more industry updates: https://lnkd.in/de5zNWmK Know more about #RASLSSConsulting: https://lnkd.in/d_daJ5Xv #CStone #Pharmalink #sugemalimab #cancer #immunotherapy #RASLSSConsulting #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #MarketExpansion #PartnerIdentification